Information on the implemented tax strategy for 2023
Polpharma Biologics S.A. is required to prepare and publish information on the executed tax strategy in order to fulfill the obligation set forth in Article 27c paragraph 1 in connection with Article 27b paragraph 2 points 1 and 2 of the Corporate Income Tax Act of February 15, 1992. We invite you to read the document.
Downloads
Polpharma Biologics S.A. is required to prepare and publish information on the executed tax strategy in order to fulfill the obligation set forth in Article 27c paragraph 1 in connection with Article 27b paragraph 2 points 1 and 2 of the Corporate Income Tax Act of February 15, 1992. We invite you to read the document.
This Code of Conduct is the first step to showing dedication to upholding continuous excellence in both business and ethical terms, and showing our care and dedication to products, clients and success.
Polpharma Biologics and the University of Warsaw have signed a cooperation agreement in an important step toward building the company’s international scientific cooperation platform.
Jerzy Starak’s billions invested in Polpharma Biologics are going to soon bear fruit in the form of new biosimilar drugs.
Polpharma Biologics is a fast-growing business that develops and manufactures
biopharmaceuticals as new molecular entities (NMEs) or biosimilars, and also
delivers biopharmaceutical CDMO services.
Polpharma Biologics announces global commercialization deal for biosimilar natalizumab, a key multiple sclerosis medicine.
Knowledge center
The place to find all the most innovative research and information on novel biologics and biosimilars.
